Skip to content

Study · Non-randomized trial · 2005

4 results

Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.

Höybye C, Thorén M, Böhm B

Journal of intellectual disability research : JIDR1 Apr 2005Cited by 60 (Europe PMC)

PMID15816811 (opens in a new tab)DOI10.1111/j.1365-2788.2005.00641.x (opens in a new tab)PepBankPUB-15816811
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome, some cognitive test results improved significantly after 6 and 18 months of GH treatment.

    In plain wordsIn adults with Prader-Willi syndrome, some cognitive test results improved during GH treatment compared with pretreatment results.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCognitive test performance
    Study

    n: not reported in source

    Comparator
    Before GH treatment
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    1.6 IU/day (0.53 mg/day) · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The results from some of the cognitive and the motor performance tests improved significantly after 6 and 18 months of GH treatment.
    3 context sentences
    Summary · context
    Nineteen patients, 9 females and 10 males, median age 25 years, mean BMI 35 kg/m2 participated in this study.
    Summary · context
    The patients were randomized to 6 months of treatment with either GH [1.6 IU/day (0.53 mg/day)] or placebo, followed by 12 months of active GH treatment.
    Summary · context
    Treatment was then stopped, and the patients were followed for an additional period of 6 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome, some motor performance test results improved significantly after 6 and 18 months of GH treatment.

    In plain wordsIn adults with Prader-Willi syndrome, some motor performance test results improved during GH treatment compared with pretreatment results.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseMotor test performance
    Study

    n: not reported in source

    Comparator
    Before GH treatment
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    1.6 IU/day (0.53 mg/day) · 6 and 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The results from some of the cognitive and the motor performance tests improved significantly after 6 and 18 months of GH treatment.
    3 context sentences
    Summary · context
    Nineteen patients, 9 females and 10 males, median age 25 years, mean BMI 35 kg/m2 participated in this study.
    Summary · context
    The patients were randomized to 6 months of treatment with either GH [1.6 IU/day (0.53 mg/day)] or placebo, followed by 12 months of active GH treatment.
    Summary · context
    Treatment was then stopped, and the patients were followed for an additional period of 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome, questionnaires showed impaired physical status, social status, and overall functioning when GH treatment stopped.

    In plain wordsIn adults with Prader-Willi syndrome, physical status, social status, and overall functioning worsened after GH stopped compared with treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreasePhysical status, social status and overall functioning after GH cessation
    Study

    n: not reported in source

    Comparator
    During GH treatment
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.6 IU/day (0.53 mg/day)As given in this study (human).

    Source sentences

    Summary
    According to the questionnaires, both the patients and the relatives/caretakers evaluated physical status rather negatively at baseline, but still, impairments in both physical and social status and overall functioning were observed when GH treatment was discontinued.
    3 context sentences
    Summary · context
    Nineteen patients, 9 females and 10 males, median age 25 years, mean BMI 35 kg/m2 participated in this study.
    Summary · context
    The patients were randomized to 6 months of treatment with either GH [1.6 IU/day (0.53 mg/day)] or placebo, followed by 12 months of active GH treatment.
    Summary · context
    Treatment was then stopped, and the patients were followed for an additional period of 6 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with Prader-Willi syndrome, self-evaluation did not change in any aspect during GH treatment.

    In plain wordsIn adults with Prader-Willi syndrome, self-evaluation did not change during GH treatment compared with pretreatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeSelf-evaluation
    Study

    n: not reported in source

    Comparator
    Before GH treatment
    Outcome group
    Quality of life · Whole body
    Studied dose
    1.6 IU/day (0.53 mg/day)As given in this study (human).

    Source sentences

    Summary
    The self-evaluation did not change in any aspect during GH treatment.
    3 context sentences
    Summary · context
    Nineteen patients, 9 females and 10 males, median age 25 years, mean BMI 35 kg/m2 participated in this study.
    Summary · context
    The patients were randomized to 6 months of treatment with either GH [1.6 IU/day (0.53 mg/day)] or placebo, followed by 12 months of active GH treatment.
    Summary · context
    Treatment was then stopped, and the patients were followed for an additional period of 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.